Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aldesleukin
Drug ID BADD_D00062
Description Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Indications and Usage For treatment of adults with metastatic renal cell carcinoma.
Marketing Status approved
ATC Code L03AC01
DrugBank ID DB00041
KEGG ID D00748
MeSH ID C082598
PubChem ID Not Available
TTD Drug ID D05PUD
NDC Product Code 76310-022; 17089-380
UNII M89N0Q7EQR
Synonyms aldesleukin | Proleukin | BAY 50-4798
Chemical Information
Molecular Formula Not Available
CAS Registry Number 110942-02-4
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory failure14.01.04.003; 22.02.06.002--
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.017--
Rhabdomyolysis15.05.05.002--
Rhinitis11.01.13.004; 22.07.03.006--
Seizure17.12.03.001--
Sepsis11.01.11.003--
Shock24.06.02.002---
Somnolence17.02.04.006; 19.02.05.003--
Stomatitis07.05.06.005--
Stupor17.02.04.007; 19.02.05.004---
Subarachnoid haemorrhage12.01.10.011; 17.08.01.010; 24.07.04.004---
Subdural haemorrhage12.01.10.006; 17.08.05.003; 24.07.04.012---
Supraventricular tachycardia02.03.03.012--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Thrombocytopenia01.08.01.002---
Thrombosis24.01.01.006---
Tracheo-oesophageal fistula03.16.02.002; 07.11.05.003; 22.04.07.003---
Transient ischaemic attack17.08.04.001; 24.04.06.005--
Urticaria10.01.06.001; 23.04.02.001--
Ventricular extrasystoles02.03.04.007---
Ventricular tachycardia02.03.04.010--
Vitiligo10.04.02.004; 23.05.02.004---
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Tubulointerstitial nephritis20.05.02.002---
Brain oedema12.01.10.010; 17.07.02.003--
Haemorrhage24.07.01.002---
Vasodilation procedure25.03.01.001---
Blood alkaline phosphatase increased13.04.02.004--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages